ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 292 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.07 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,763,104 | +47.0% | 214,481 | +95.1% | 0.01% | +40.0% |
| Q2 2023 | $3,919,819 | -1.6% | 109,922 | -29.9% | 0.01% | -16.7% |
| Q1 2023 | $3,984,752 | -0.4% | 156,880 | +59.0% | 0.01% | 0.0% |
| Q4 2022 | $4,001,771 | -99.9% | 98,663 | -23.6% | 0.01% | -14.3% |
| Q3 2022 | $4,270,324,000 | +156.2% | 129,208 | +173.0% | 0.01% | +133.3% |
| Q2 2022 | $1,666,701,000 | -32.4% | 47,336 | -11.7% | 0.00% | 0.0% |
| Q1 2022 | $2,465,570,000 | -22.3% | 53,611 | +12.0% | 0.00% | -40.0% |
| Q4 2021 | $3,173,648,000 | +76.8% | 47,868 | +66.5% | 0.01% | +66.7% |
| Q3 2021 | $1,795,237,000 | +10.5% | 28,756 | +46.6% | 0.00% | +50.0% |
| Q2 2021 | $1,624,266,000 | -13.0% | 19,612 | -30.3% | 0.00% | -33.3% |
| Q1 2021 | $1,866,494,000 | +12.9% | 28,148 | +30.6% | 0.00% | 0.0% |
| Q4 2020 | $1,653,838,000 | +156.2% | 21,554 | +43.8% | 0.00% | +200.0% |
| Q3 2020 | $645,556,000 | +9.9% | 14,992 | +10.3% | 0.00% | 0.0% |
| Q2 2020 | $587,254,000 | -24.6% | 13,597 | -49.8% | 0.00% | -50.0% |
| Q1 2020 | $778,919,000 | -47.6% | 27,074 | +15.6% | 0.00% | -33.3% |
| Q4 2019 | $1,485,150,000 | +197.9% | 23,414 | +32.4% | 0.00% | +200.0% |
| Q3 2019 | $498,476,000 | +64.4% | 17,689 | +54.6% | 0.00% | 0.0% |
| Q2 2019 | $303,134,000 | -15.3% | 11,439 | -41.4% | 0.00% | 0.0% |
| Q1 2019 | $358,082,000 | +556.3% | 19,514 | +585.7% | 0.00% | – |
| Q3 2018 | $54,558,000 | +41.0% | 2,846 | 0.0% | 0.00% | – |
| Q2 2018 | $38,706,000 | +1764.5% | 2,846 | +888.2% | 0.00% | – |
| Q1 2018 | $2,076,000 | +95.8% | 288 | 0.0% | 0.00% | – |
| Q4 2017 | $1,060,000 | -15.0% | 288 | 0.0% | 0.00% | – |
| Q3 2017 | $1,247,000 | -86.4% | 288 | -94.9% | 0.00% | – |
| Q2 2017 | $9,147,000 | +57.4% | 5,646 | +50.6% | 0.00% | – |
| Q4 2016 | $5,813,000 | -81.0% | 3,750 | -10.0% | 0.00% | – |
| Q3 2016 | $30,627,000 | +140.0% | 4,167 | +73.7% | 0.00% | – |
| Q2 2016 | $12,763,000 | – | 2,399 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |